NCT04984772Enrolling by invitation
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
Understanding Treatment Outcomes of HIV/HBV Coinfection: A Prospective Cohort of HIV/HBV-coinfected Patients in Europe
Source: ClinicalTrials.gov · Last updated 1 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The overall aim of the project is to establish an international multi-cohort research platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our understanding of the determinants of treatment outcomes.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1107 (estimated)
- First submitted
- 30 Jun 2021
- Start date
- 2 Oct 2001
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Hepatitis B, HIV
- NCT number
- NCT04984772
What you commit to
- Study type: Observational
- Planned participants: 1107
- From 2 Oct 2001 to the primary completion date, 31 Dec 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Study participant from contributing cohort
- 2 positive HBsAg tests more than 6 months apart
- At least 2 data points (baseline and 2 years after TDF/TAF start either as available data or stored sample
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Related publications
- Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe.JHEP Rep · 2026 · PMID 41551412
This page is information, not medical advice. Discuss any trial with your doctor.